BridgeBio Oncology Therapeutics Inc.

NASDAQ:BBOT

Biotechnology

Healthcare
$1.81 -0.39%

-$0.03 today

Market cap
$144.85M
Beta
0.29
P/E (TTM)
-1.5
EPS (TTM)
-$4.95
52W Low $7.00High $14.87

Volume 0.58M

Average 0.37M

BBOT Common Stock

The par or stated value of issued common shares, plus paid-in capital where reported together.

BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT

Common Stock · Q1 FY2026 · quarter ended Mar 2026

Common stock remains negative

Q1 FY2026 common stock was $8K, compared with $0 a year earlier. Over 3 fiscal years it compounded at +202.9% a year.

Context

  • Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Common stock increased in 2 of the last 3 fiscal years.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8K+0.0% QoQ
Last fiscal yearDec 2025
$8K-100.0% YoY
Year agoMar 2025
$0— since
Common Stock past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-100.0%——
3-year CAGR+202.9%——
5-year CAGR——
10-year CAGR——

Common Stock history

USD · from the balance sheet

Latest · FY2025
8K USD
Year-over-year change
-100.0%
4-year CAGR
+129.6%

Common Stock vs competitors

How BBOT compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock is compared through growth and share of total assets rather than absolute size.
  • Common stock amounts to 0.0% of total assets for BBOT, versus a peer median of 0.0%.
BBOT Competitors
Common Stock for BBOT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
XNCRXencor, Inc.Jun 2026$744K USD+4.2%+6.1%0.1%
OCSOculis Holding AGMar 2026CHF 618.15K CHF+11.4%+147.0%0.3%
TNGXTango Therapeutics, Inc.Sep 2026$169K USD+50.9%+15.6%0.0%
URGNUroGen Pharma Ltd.Mar 2026$134K USD+6.3%+28.3%0.1%
NRIXNurix Therapeutics, Inc.Aug 2026$109K USD+41.6%+29.5%0.0%
SEPNSepterna, Inc.Sep 2026$47K USD+4.4%+146.6%0.0%
ANABAnaptysBio, Inc.Mar 2026$29K USD-3.3%-1.2%0.0%
BBOTBridgeBio Oncology Therapeutics Inc.Mar 2026$8K USD—+202.9%0.0%
PHATPhathom Pharmaceuticals, Inc.Mar 2026$7K USD+16.7%+26.0%0.0%
KODKodiak Sciences Inc.Sep 2026$6K USD+20.0%+6.3%0.0%
Peer median (excluding BBOT) —+11.4%+26.0%0.0%

Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents0001.7M373.69M
Short-term Investments000051.77M
Net Receivables0000386K
Inventory00000
Other Current Assets0000(386K)
Total Current Assets0001.95M425.46M
Property, Plant & Equipment (Net)00000
Goodwill00000
Intangible Assets00000
Long-term Investments000192.45M132K
Tax Assets00000
Other Non-current Assets144.28K144.58K332.89K25.13K22.79M
Total Non-current Assets144.28K144.58K332.89K192.47M22.92M
Total Assets144.28K144.58K332.89K194.42M448.38M
Account Payables00001.37M
Short-term Debt36.96K43.11K70.1K00
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities00005.75M
Total Current Liabilities162.64K166.46K396.46K187.52K35.04M
Long-term Debt00002.24M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities0005.52M0
Total Non-current Liabilities0005.52M2.24M
Total Liabilities162.64K166.46K396.46K5.71M37.29M
Common Stock288288460192.45M8K
Retained Earnings(43.36K)(46.88K)(88.57K)(3.73M)(356.57M)
Accumulated OCI000016K
Other Stockholders Equity0172000
Minority Interest00000
Total Equity(18.36K)(21.88K)(63.57K)188.72M411.1M
Total Debt36.96K43.11K70.1K02.77M
Net Debt36.96K43.11K70.1K(1.7M)(370.92M)

BridgeBio Oncology Therapeutics Inc.

NASDAQ:BBOT

Intrinsic Alpha fair value

Locked

Current Price

$1.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.